InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested
InMed Pharmaceuticals Inc. shares slipped in early Nasdaq pre-market trading on Wednesday, giving back part of a surge sparked by its all-stock merger agreement with privately held Mentari Therapeutics and a planned $290 million financing.